삼양바이오팜

0120G0KOSPI의약품 제조업

47.4 / 100

Reference Date: 2026-06-10

Financial Score17.5 / 40

News Sentiment16.9 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 29.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Samyang Biopharm operates in three main business segments: medical devices, pharmaceuticals, and new drug development. Key products include biodegradable surgical sutures and hemostatic agents in the medical device sector, and anticancer drugs for solid and blood cancers in the pharmaceutical sector. The company is developing gene therapy platforms (SENS) for new drug research, with medical devices contributing 62.5% of total revenue.

Number of Employees

407people

Average Salary

79.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

171.56Industry Average 11.930.0Point

14.4x industry avg (risky)

PBR

1.63Industry Average 0.891.0Point

1.8x industry avg (risky)

ROE

—Industry Average 4.013.5Point

Debt Ratio

1.29Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Positive
삼양바이오팜, 차세대 RNA 전달체 플랫폼 주목-유안타
삼양바이오팜의 차세대 RNA 전달 플랫폼 SENS가 시장 경쟁력 강화로 긍정적 평가를 받았다.
Neutral
[바이오스냅] 동아쏘시오그룹 수석문화재단, 장학증서 수여식
관련성이 낮은 동아쏘시오그룹의 장학증서 수여식 소식으로 삼양바이오팜의 직접적인 영향은 미미함.

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 51,600Won52-week high 142,70052-week low 30,200

1-month return0.0Point

1m -29.32% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]2026-06-01
Neutral기업지배구조보고서공시2026-06-01
Neutral분기보고서 (2026.03)2026-05-15